Psychopharmacotherapy of somatic symptoms disorders

International Review of Psychiatry

Volumn 25, Issue 1, 2013, Pages 107-115

  Somashekar, Bettahalasoor ^a   Jainer, Ashok ^a   Wuntakal, Balaji ^b  

^a University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; OPIPRAMOL; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALGESIC ACTIVITY; BODY DYSMORPHIC DISORDER; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; CONVERSION DISORDER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DSM-5; DSM-IV; ELECTROCONVULSIVE THERAPY; FIBROMYALGIA; HUMAN; HYPOCHONDRIASIS; ICD-10; ICD-11; IRRITABLE COLON; META ANALYSIS; PRIORITY JOURNAL; PSYCHOGENIC PAIN; PSYCHOPHARMACOTHERAPY; PSYCHOSOMATIC DISORDER; REVIEW; SOMATIZATION; SOMATOFORM DISORDER; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; ILLNESS BEHAVIOR; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOFORM DISORDERS;

EID: 84873616285     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2012.729758     Document Type: Review

References (48)

1. Altamura, A. C., DiRosa, A., Ermentini, A., Guaraldi, G. P., Invvernizzi, G., Rudas, N. & Tacchini, G. (2003). Levosulpiride in somatoform disorders: A double blind placebo-controlled cross-over study, International Journal of Psychiatry in Clinical Practice, 7, 155-159.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association.
3. Bass, C. & Benjamin, S. (1993). The management of chronic somatisation. British Journal of Psychiatry, 162, 472-480.
4. Bass, C., Peveler, R. & House, A. (2001). Somatoform disorder: Severe psychiatric illnesses neglected by psychiatrists. British Journal of Psychiatry, 179, 11-14.
5. Chaturvedi, S.K., Upadhyaya, M.P. & Rao, S. (1988). Somatic symptoms in a community clinic. Indian Journal of Psychiatry, 30, 369-374.
6. Fallon, B.A. (2004). Pharmacotherapy of somatoform disorders. Journal of Psychosomatic Research, 56, 455-460.
7. Fallon, B.A., Liebowitz, M.R., Salman, E., Schneier, F.R., Jusino, C., Hollander, E. & Klein, D.F. (1993). Fluoxetine for hypochondriacal patients without major depression. Journal of Clinical Psychopharmacology, 13, 438-441.
8. Fallon, B.A., Petkova, E., Skritskaya, N., Sanchez-Lacay, A., Schneier, F., Vermes, D., . . . Liebowitz, M.R. (2008). A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. Journal of Clinical Psychopharmacology, 28, 638-645.
9. Fallon, B.A., Schneier, F.R., Marshall, R., Campeas, R., Vermes, D., Goetz, D. & Liebowitz, M.R. (1996). The pharmacotherapy of hypochondriasis. Psychopharmacology Bulletin, 32, 607-611.
10. Fink, P. & Rosendal, M. (2008). Recent developments in the understanding and management of functional somatic symptoms in primary care. Current Opinion in Psychiatry, 21, 182-188.
11. Fishbain, D.A., Cutler, R.B. & Rosomoff, H.L. (1998). Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosomatic Medicine, 60, 503-509.
12. Garcia-Campayo, J. & Sanz-Carrillo, C. (2002). Topiramate as a treatment for pain in multisomatoform disorder patients: An open trial. General Hospital Psychiatry, 24, 417-421.
13. Greeven, A., van Balkom, A.J., Visser, S., Merkelbach, J.W., van Rood, Y.R., van Dyck, R., . . . Spinhoven, P. (2007) C ognitive behavior therapy and paroxetine in the treatment of hypochondriasis: A randomized controlled trial. American Journal of Psychiatry, 164, 91-99.
14. Han, C., Pae, C., Lee, B., Ko, Y., Masand, P.S., Patker, A.A., . . . Jung, I. (2008). Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: A 12 week prospective, open-label, randomized, parallel-group trial. Clinical Drug Investigation, 28, 251-261.
15. Hollander, E., Allen, A., Kwon, J., Aronowitz, B., Schmeidler, J., Wong, C. & Simeon, D. (1999). Clomipramine vs desipramine crossover trail in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Archives of General Psychiatry, 56, 1033-1039.
16. Isper, J.C., Sander, C. & Stein, D.J. (2009). Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database of Systematic Reviews, 1, CD005332. doi:10.1002/ 14651858.CD005332.pub2.
17. Jeffery, L.J. & Kroenke, K. (2008). Prevalence, impact and prognosis of multisomatoform disorder in primary care: A 5-year follow-up study. Psychosomatic Medicine, 70, 430-434.
18. Kroenke, K. (2003). Patients presenting with somatic complaints: Epidemiology, psychiatric co-morbidity and management. International Journal of Methods in Psychiatric Research, 12, 34-43.
19. Kroenke, K. (2007). Efficacy of treatment for somatoform disorders: A review of randomized controlled trials. Psychosomatic Medicine, 69, 881-888.
20. Kroenke, K. & Mangelsdorff, A.D. (1989). Common symptoms in ambulatory care: Incidence, evaluation, therapy and outcome. American Journal of Medicine, 86, 262-266.
21. Lowe, B., Mundt, C., Herzog, W., Brunner, R., Backenstrass, M., Kronmuller, K. & Henningsen, P. (2008). Validity of current somatoform disorder diagnoses: Perspectives for classification in DSM-V and ICD-11. Psychopathology, 41, 4-9.
22. Luo, Y., Zhang, M.Y., Wu, W.Y., Li, C.B., Lu, Z. & Li, Q.W. (2009). A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 1522-1525.
23. Lynch, M.E. (2001). Antidepressants as analgesics: A review of randomized controlled trials. Journal of Psychiatry of Neuroscience, 26, 30-36.
24. Magarinos, M., Zafar, U., Nissenson, K.K. & Blanco, C. (2002). Epidemiology and treatment of hypochondriasis. CNS Drugs, 16, 9-22.
25. Menza, M., Lauritano, M., Allen, L., Warman, M., Ostello, F., Hamer, R.M. & Escobar, J. (2001). Treatment of somatisation disorder with nefazodone: A prospective open-label study. Annals of Clinical Psychiatry, 13, 153-158.
26. Muller, J.E., Wentzel, I., Koen, L., Niehaus, D.J.H., Seedat, S. & Stein, D.J. (2008). Escitalopram in the treatment of multisomatoform disorder: A double-blind placebo-controlled trail. International Clinical Psychopharmacology, 23, 43-48.
27. Muller, T., Mannel, M., Murck, H. & Rahlfs, V.W. (2004). Treatment of somatoform disorders with St John's wort: A randomized double-blind and placebo-controlled trial. Psychosomatic Medicine, 66, 538-547.
28. NICE (2005). Obsessive compulsive disorder: Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. Clinical Guideline 31. London: National Institute for Health and Clinical Excellence.
29. Noyes, R, Jr, Happel, R.L., Muller, B.A., Holt, C.S., Kathol, R.L., Sieren, L.R. & Amos, J.J. (1998). Fluvoxamine for somatoform disorders: An open trial. General Hospital Psychiatry, 20, 339-344.
30. Noyes, R, Jr, Holt, C.S. & Kathol, R.G. (1995). Somatization. Diagnosis and management. Archives of Family Medicine, 4, 790-795.
31. O'Malley, P.G., Jackson, J.L., Santoro, J., Tomkins, G., Balden, E. & Kroenke, K. (1999). Antidepressant therapy for unexplained medical symptoms and syndromes. Journal of Family Practice, 48, 980-90.
32. Perugi, G., Giannotti, D., Di Vaio, S., Frare, F., Saettoni, M. & Cassano, G.B. (1996) Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). International Clinical Psychopharmacology, 11, 247-254.
33. Phillips, K.A. (2004). Body dysmorphic disorder: Recognizing and treating imagined ugliness. World Psychiatry, 3, 12-17.
34. Phillips, K.A. & Hollander, E. (2008). Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. Body Image, 5, 13-27. doi:10.1016/j. bodyim.2007.12.003.
35. Phillips, K.A. & Najar, F. (2003). An open label study of citalopram in body dysmorphic disorder. Journal of Clinical Psychiatry, 64, 715-720.
36. Phillips, K.A., Albertini, R.S. & Rasmussen, S.A. (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry, 59, 381-388.
37. Phillips, K.A., Albertini, R.S., Siniscalchi, J.M., Khan, A.H. & Robinson, M. (2001). Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study. Journal of Clinical Psychiatry, 62, 721-727.
38. Phillips, K.A., Dwight, M.M. & McElroy, S.L. (1998). Efficacy and safety of fluvoxamine in body dysmorphic disorder. Journal of Clinical Psychiatry, 59, 165-171.
39. Pilowsky, L. (1968). The response to treatment in hypocho ndriacal disorders. Australian and New Zeeland Journal of Psychiatry, 2, 88-92.
40. Schreiber, S., Bleich, A. & Pick, C.G. (2002). Venlafaxine and mirtazapine: Different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects-A possible opioid involvement in severe depression. Journal of Molecular Neuroscience, 18, 143-149.
41. Stone, A.B. (1993). Treatment of hypochondriasis of clomipramine . Journal Clinical Psychiatry, 54, 200-201.
42. Sumathipala, A. (2007). What is the evidence for the efficacy of treatment for somatoform disorder? A critical review of previous intervention studies. Psychosomatic Medicine, 69, 889-900.
43. Sussman, N. (2003). SNRIs versus SSRIs: Mechanisms of action in treating depressions and painful physical symptoms. Primary Care Companion Journal of Clinical Psychiatry, 5, 19-26.
44. Volz, H.P., Moller, H.J., Reimann, I. & Stoll, K.D. (2000). Opipramol for the treatment of somatoform disorders: Results of a placebo-controlled trial. European Neuropsychopharmacology, 10, 211-217.
45. Volz, H.P., Murck, H., Kasper, S. & Moller, H.J. (2002). St. John's wort extract (LI160) in somatoform disorders: Results of a placebo-controlled trial. Psychopharmacology, 164, 294-300.
46. Wesner, R.B. & Noyes, R. (1991). Imipramine: An effective treatment for illness phobia. Journal of Affective Disorders, 22, 43-48.
47. Wessely, S., Nimnuan, C. & Sharpe, M. (1999). Functional somatic syndromes: One or many? Lancet, 354, 936-939. doi:10.1016/S0140-6736(98)08320-2.
48. WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines . Geneva: World Health Organization.